ALDATU BIOSCIENCES INC
PANDAA adaptive PCR diagnostic technology that automatically compensates for pathogen genomic variation
- Sector
- Medtech
- Headquarters
- Watertown, MA
- Founded
- 2014
- Latest Form D
- $100K, Mar 2016
- Total capital
- $19.8M
- Federal grants
- $19.7M
- 17 awards · 2015–2025
- Rank in peer group#15 of 112
- Private capital raised
- $100K
- 1 Form D · last Mar 2016
- 128 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- None on recordNo USPTO grants. Applications publish after 18 months.
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$975K
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$987K
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$943K
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$931K
- Federal grantHealth and Human S · Phase II · Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$2M
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$1.9M
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$964K
- Private capital raisedForm D · SEC · 1st filing$100K
Show 10 earlier federal awards
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$829K
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$1.7M
- Federal grantHealth and Human S · Phase II · PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$866K
- Federal grantHealth and Human S · Phase I · PANDAA for universal, pan-lineage molecular detection of Lassa fever infection$300K
- Federal grantHealth and Human S · Phase II · PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$967K
- Federal grantHealth and Human S · Phase II · PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$974K
- Federal grantHealth and Human S · Phase II · PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$2.9M
- Federal grantHealth and Human S · Phase II · PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$998K
- Federal grantHealth and Human S · Phase II · A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$691K
- Federal grantHealth and Human S · Phase II · A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$773K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
12months
from ALDATU BIOSCIENCES INC’s first federal award to its first private round.
- First federal award · Mar 2015
- Health and Human S · $773K
- First Form D · Mar 2016
- $100K · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 112 peers
Line = medianMedtech · Instrument
- Federal grants#15 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Iain J. MacleodResearcherExecutive Officer, DirectorLinked by $8.5M in grants as PI
- David M. RaiserExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
No granted patents are on record.
USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.
Checked: USPTO granted patents and published applications · Oct 23, 2026
Related companies, and why
- DAVINCI BIO, INC.Similar federal contract value in Medtech · null in contracts
- CYTOVERIS INCSimilar federal contract value in Medtech · null in contracts
- Potrero Medical, Inc.Similar federal contract value in Medtech · null in contracts
- REBISCAN, LLCSimilar federal contract value in Medtech · null in contracts
- Applied Research and PhotonicsSimilar federal contract value in Medtech · null in contracts
- CHRONO THERAPEUTICS, INC.Similar federal contract value in Medtech · null in contracts
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .